Literature DB >> 16396525

Inclusion of patients with severe mental illness in clinical trials: issues and recommendations surrounding informed consent.

Sander P K Welie1, Ron L P Berghmans.   

Abstract

Modern medicine would be unthinkable without the possibility of administering pharmaceuticals and other evidence-based interventions. The development of these interventions requires scientific research, ultimately with human subjects. This venture raises ethical, legal and human rights issues, which are addressed in numerous national and international declarations and regulations. In these documents, special attention is usually directed towards research involving vulnerable groups, such as children, pregnant women, unemployed persons, refugees, patients with psychiatric disorders, dementia or mental retardation, and those who are dying. In relation to patients with psychiatric disorders, two important and mutually connected ethical questions can be posed. Firstly, is research with persons who have severe psychiatric illnesses permissible? And, secondly, how can the mental capacity of prospective research subjects be assessed? We investigate these questions using the Dutch legal system as an example. Regarding the first question, the Dutch Medical-Scientific Research on Human Subjects Act (1998) presents a detailed regulation that is in line with relevant international documents, such as the Convention on Human Rights and Biomedicine (1997). In the Dutch statute, the possibilities for research involving subjects who lack mental capacity are limited, but not completely excluded. Under certain conditions, two types of research are exempted from the general prohibition of research with such subjects that is included in article 4 of the statute. These two types are (i) therapeutic research and (ii) non-therapeutic research that could not take place without the participation of subjects from the category to which the mentally incapacitated person belongs. The conditions pertain to ethical and scientific review, insurance, written proxy consent and respect for resistance by the subject. An extra condition for the permissibility of non-therapeutic research is that the risks for the prospective subject are negligible and the burdens minimal. Although the Dutch regulation obviously does not solve all problems, it is relatively clear when compared with the situation in other European countries, such as Belgium, France, Germany, and England and Wales. Regarding the second question, two basic factors need to be considered when defining 'mental capacity'. These relate to the assumption of competence and to the task-specificity of capacity. The crucial issue in assessing mental capacity is not whether a psychiatric diagnosis is present, but whether the patient has the mental abilities required to make the decision at hand in a meaningful way. In establishing an appropriate standard for capacity assessment, several interests have to be weighed. The ethical demands of protection of subjects and stimulation of scientific research may be balanced by attempting to enhance patients' mental capacity. The procedure of 'experienced consent' seems promising in this regard, although this approach entails its own ethical problems.

Entities:  

Mesh:

Year:  2006        PMID: 16396525     DOI: 10.2165/00023210-200620010-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  43 in total

1.  Decision-making capacity.

Authors:  M J Gunn; J G Wong; I C H Clare; A J Holland
Journal:  Med Law Rev       Date:  1999       Impact factor: 1.267

2.  The Prussian regulation of 1900: early ethical standards for human experimentation in Germany.

Authors:  Jochen Vollmann; Rolf Winau
Journal:  IRB       Date:  1996 Jul-Aug

3.  The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia.

Authors:  William T Carpenter; Paul S Appelbaum; Robert J Levine
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

4.  Therapeutic misconception and the appreciation of risks in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Thomas Grisso; Michelle Renaud
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

Review 5.  Instruments to assess decision-making capacity: an overview.

Authors:  Astrid Vellinga; Johannes H Smit; Evert van Leeuwen; Willem van Tilburg; Cees Jonker
Journal:  Int Psychogeriatr       Date:  2004-12       Impact factor: 3.878

6.  Experienced consent in geriatrics research: a new method to optimize the capacity to consent in frail elderly subjects.

Authors:  M G Rikkert; J H van den Bercken; H A ten Have; W H Hoefnagels
Journal:  J Med Ethics       Date:  1997-10       Impact factor: 2.903

Review 7.  Ethical concerns about relapse studies.

Authors:  A E Shamoo; T J Keay
Journal:  Camb Q Healthc Ethics       Date:  1996       Impact factor: 1.284

Review 8.  Advance directives for non-therapeutic dementia research: some ethical and policy considerations.

Authors:  R L Berghmans
Journal:  J Med Ethics       Date:  1998-02       Impact factor: 2.903

9.  False hopes and best data: consent to research and the therapeutic misconception.

Authors:  P S Appelbaum; L H Roth; C W Lidz; P Benson; W Winslade
Journal:  Hastings Cent Rep       Date:  1987-04       Impact factor: 2.683

Review 10.  National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders.

Authors:  Dennis S Charney; Charles B Nemeroff; Lydia Lewis; Sally K Laden; Jack M Gorman; Eugene M Laska; Michael Borenstein; Charles L Bowden; Arthur Caplan; Graham J Emslie; Dwight L Evans; Barbara Geller; Lenore E Grabowski; Jay Herson; Ned H Kalin; Paul E Keck; Irving Kirsch; K Ranga R Krishnan; David J Kupfer; Robert W Makuch; Franklin G Miller; Herbert Pardes; Robert Post; Mildred M Reynolds; Laura Roberts; Jerrold F Rosenbaum; Donald L Rosenstein; David R Rubinow; A John Rush; Neal D Ryan; Gary S Sachs; Alan F Schatzberg; Susan Solomon
Journal:  Arch Gen Psychiatry       Date:  2002-03
View more
  4 in total

1.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

2.  [Research on humans suffering from dementia].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

3.  Parent ratings of ability to consent for clinical trials in fragile X syndrome.

Authors:  Donald B Bailey; Melissa Raspa; Anne Wheeler; Anne Edwards; Ellen Bishop; Carla Bann; David Borasky; Paul S Appelbaum
Journal:  J Empir Res Hum Res Ethics       Date:  2014-07       Impact factor: 1.742

Review 4.  [Ethical questions in clinical research with the mentally ill].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2008-09       Impact factor: 1.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.